Zhang Ying, Li Tao, Qiu Yumin, Zhang Tao, Guo Pengbo, Ma Xiaomin, Wei Qing, Han Lihui
aDepartment of Immunology, Shandong University School of Medicine bDepartment of Infectious Diseases, Provincial Hospital Affiliated to Shandong University cDepartment of Epidemiology and Biostatistics, School of Public Health, Shandong University, Jinan, China.
Medicine (Baltimore). 2017 Jan;96(2):e5642. doi: 10.1097/MD.0000000000005642.
Unique change of circulating microRNAs (miRNAs) was recognized to occur in early oncogenesis, which conferred it the potential as biomarkers for early detection of cancer. However, its diagnostic capability for hepatocellular carcinoma (HCC) has not been fully understood. In this study, microarray analysis was applied to screen the initial candidate miRNA from both the supernatants of anoikis-resistant cellular models and the sera samples of HCC patients. The selected differentially expressed miRNAs were further verified in 115 HCC patients and 40 health controls by qRT-PCR. Among these, 4 miRNAs (miR-16-2-3p, 92a-3p, 107, and 3126-5p) were significantly changed in HCC patients compared with controls. Logistic regression analysis identified a 3-miRNA panel (miR-92-3p, miR-107, and miR-3126-5p) as valuable diagnostic marker for HCC, especially for early stage patients (AUC = 0.975) and for low-level AFP HCC patients (AUC = 0.971). In addition, the combination of 3-miRNA panel and AFP was even more effective for discriminating the early stage HCC patients (AUC = 0.988) and low-level AFP HCC patients (AUC = 0.989) from control. In conclusion, diagnostic efficacy of the combination of 3-miRNA panel and AFP was powerful for HCC diagnosis, especially in early tumor screening and low-level AFP patients.
循环微小RNA（miRNA）的独特变化被认为发生在肿瘤发生早期，这使其具有作为癌症早期检测生物标志物的潜力。然而，其对肝细胞癌（HCC）的诊断能力尚未完全明确。在本研究中，应用微阵列分析从失巢凋亡抗性细胞模型的上清液和HCC患者的血清样本中筛选初始候选miRNA。通过qRT-PCR在115例HCC患者和40例健康对照中进一步验证所选的差异表达miRNA。其中，与对照组相比，4种miRNA（miR-16-2-3p、92a-3p、107和3126-5p）在HCC患者中发生了显著变化。逻辑回归分析确定了一个由3种miRNA组成的组合（miR-92-3p、miR-107和miR-3126-5p）作为HCC的有价值诊断标志物，尤其对于早期患者（AUC = 0.975）和低水平甲胎蛋白（AFP）的HCC患者（AUC = 0.971）。此外，3种miRNA组合与AFP联合使用在区分早期HCC患者（AUC = 0.988）和低水平AFP的HCC患者（AUC = 0.989）与对照组方面更有效。总之，3种miRNA组合与AFP联合使用对HCC诊断具有强大的诊断效能，尤其是在早期肿瘤筛查和低水平AFP患者中。
